Abstract:Adoptive cell therapy using chimeric antigen receptor (CAR) technology has become mainstream by employing advanced engineering platforms to promote cancer immunotherapy. CAR T cells have shown remarkable efficacy in the treatment of hematological malignancies; however, the value of this therapy remains inconclusive in the context of solid tumors. Immunotherapy of solid tumors is restrained by several obstacles including the presence of an immunosuppressive tumor microenvironment (TME), limited tumor trafficking, inhibited immune cell infiltration, absence of tumor-specific antigens, and off-target toxicity and adverse events associated with these therapies. Despite recent advances in CAR T cell construction, including the integration of co-stimulatory domains and the creation of armed CAR T cells, with promising outcomes in the treatment of some solid tumors, there are still many unresolved obstacles that need to be overcome. To surmount these impediments to effective CAR T cell therapies, other immune cells, such as natural killer cells and macrophages, have been engineered to serve as appealing alternatives for successful cancer immunotherapy of solid tumors. CAR NK cells demonstrate significant clinical advantages due to their ready availability and minimal toxicity. CAR macrophage (M) cells provide considerable therapeutic potential due to their ability to penetrate the TME of solid tumors. In this review, we comprehensively examine the latest developments and prospects of engineered immune cell-based cancer immunotherapies specifically designed for treating solid tumors. In addition, we provide a concise overview of current clinical trials that are examining the safety and effectiveness of modified immune cells, such as CAR T, CAR NK, and CAR M, in their ability to specifically target solid tumors and promote improved therapeutic outcomes in patients with diverse solid cancers.

Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

Recent advances and progress in immunotherapy of solid cancers

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

CAR T cell therapy: Current limitations and advancements in treating solid tumors

CAR-T cell therapy: current limitations and potential strategies

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities